Liberati A M, Voelkel J G, Borden E C, Coates A S, Citrin D L, Bryan G T
Cancer Immunol Immunother. 1982;13(2):140-4. doi: 10.1007/BF00205315.
Fifty-nine evaluable patients with stage III bronchogenic carcinoma, participating in a randomized clinical trial evaluating the effect of adjuvant immunotherapy with levamisole or BCG in the treatment of clinically advanced lung cancer, were studied for their immunocompetence by in vitro and in vivo assays. Immunological tests consisted of measurements of natural killer (NK) cell and killer (K) cell cytotoxicity, skin testing reactivity to recall antigens, absolute lymphocyte count, and serum immunoglobulin (Ig) levels. Pretherapy K cell cytotoxic levels, skin test reactivity to trichophyton antigen, and increased IgA levels were predictive of the overall clinical course. Despite non-specific immunotherapy, progressive decline of NK and K cell cytotoxicity occurred during the course of the disease. These findings, however, were of limited clinical value. Initial performance status and disease extent significantly influenced time to progression and survival. Little further prognostic information was obtained from the immunological tests over those provided by clinical performance status and disease extent. No statistically significant differences were found in either time to progression or survival between controls and patients receiving either levamisole or BCG.
59例可评估的Ⅲ期支气管癌患者参与了一项随机临床试验，该试验旨在评估左旋咪唑或卡介苗辅助免疫疗法对临床晚期肺癌的治疗效果。通过体外和体内试验对这些患者的免疫能力进行了研究。免疫测试包括测量自然杀伤（NK）细胞和杀伤（K）细胞的细胞毒性、对回忆抗原的皮肤试验反应性、绝对淋巴细胞计数以及血清免疫球蛋白（Ig）水平。治疗前的K细胞细胞毒性水平、对毛癣菌抗原的皮肤试验反应性以及IgA水平升高可预测总体临床病程。尽管进行了非特异性免疫治疗，但在疾病过程中NK和K细胞的细胞毒性仍逐渐下降。然而，这些发现的临床价值有限。初始身体状况和疾病范围显著影响疾病进展时间和生存期。与临床身体状况和疾病范围所提供的信息相比，免疫测试几乎没有提供更多的预后信息。在对照组与接受左旋咪唑或卡介苗治疗的患者之间，疾病进展时间或生存期均未发现统计学上的显著差异。
